<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The incidence of <z:e sem="disease" ids="C0036572,C0009951" disease_type="Disease or Syndrome;Sign or Symptom" abbrv="">convulsion</z:e> and associated factors were retrospectively analyzed in 23 patients with symptomatic <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) who underwent a total of 31 intra-arterial infusion of fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> (IAFH) procedures in 49 vessels </plain></SENT>
<SENT sid="1" pm="."><plain>Fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> was administered by superselective infusion via a microcatheter positioned at the proximal portion of the affected artery </plain></SENT>
<SENT sid="2" pm="."><plain>Thirteen procedures were performed by manually controlled infusion of 30-75 mg fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> (1.2-3.75 mg/ml) for approximately 10 minutes </plain></SENT>
<SENT sid="3" pm="."><plain>Eighteen procedures were performed by continuous infusion of 60 mg fasudil <z:chebi fb="16" ids="36807">hydrochloride</z:chebi> (1.2 mg/ml) by infusion pump at a constant rate of 3 mg/min </plain></SENT>
<SENT sid="4" pm="."><plain>Neurological improvement was observed after 18 of 22 procedures in patients with neurological deterioration due to vasospasm </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0036572,C0009951" disease_type="Disease or Syndrome;Sign or Symptom" abbrv="">Convulsion</z:e> during IAFH developed in 4 patients, <z:hpo ids='HP_0000001'>all</z:hpo> treated by manual infusion (p &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>The manual infusion method (p &lt; 0.05) and infusion rate greater than 3 mg/min (p &lt; 0.01) were significantly associated with the incidence of <z:e sem="disease" ids="C0036572,C0009951" disease_type="Disease or Syndrome;Sign or Symptom" abbrv="">convulsion</z:e> during IAFH </plain></SENT>
<SENT sid="7" pm="."><plain>IAFH was effective for treating <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> following aneurysmal SAH </plain></SENT>
<SENT sid="8" pm="."><plain>IAFH at a constant rate of 3 mg/min delivered by infusion pump improved the symptoms of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and prevented <z:mp ids='MP_0000947'>convulsions</z:mp> during IAFH </plain></SENT>
</text></document>